Driehaus Capital Management Reduces $3M in Kymera Therapeutics, Inc. ($KYMR)
Driehaus Capital Management trimmed its Kymera Therapeutics holdings by 25,655 shares, reflecting a 2.4% decrease.
Key Points
- Driehaus Capital Management trimmed its stake in Kymera Therapeutics by 25,655 shares, a 2.4% decrease, ending with 1,043,583 shares valued at $102.53 million.
- Kymera Therapeutics, trading at $98.25 on Wednesday, has a market cap of about $8.18 billion and a forward P/E of -22.89.
- Insiders, including Chief Business Officer Noah Goodman, made several transactions, and analysts maintain a strong buy consensus with a target mean price of $119.19.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Driehaus Capital Management has trimmed its stake in Kymera Therapeutics, Inc. (NasdaqGM: KYMR). In its latest filing with the SEC, the firm reported selling 25,655 shares, reducing its position by 2.4% to 1,043,583 shares. The value of this holding is approximately $102.53 million as of the reporting period ending May 15, 2026.
Driehaus Capital Management vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Driehaus Capital Management's Kymera Therapeutics Position
Driehaus Capital Management reduced its stake in Kymera Therapeutics by 25,655 shares, representing a 2.4% decrease from its previous holding. The firm's total shares now stand at 1,043,583, valued at around $102.53 million.
Other Institutional Activity in Kymera Therapeutics
FMR LLC grew its holdings in Kymera Therapeutics by 2,771,376 shares, ending with 11,699,950 shares worth about $974.49 million. Meanwhile, Baker Bros. Advisors LP and Avoro Capital Advisors LLC maintained their positions with 8,657,242 and 7,474,747 shares, valued at $721.06 million and $622.57 million, respectively. Price T Rowe Associates Inc /MD/ trimmed its stake by 98,488 shares, resulting in 6,060,847 shares valued at $504.81 million. T. Rowe Price Investment Management, Inc. significantly increased its holdings by 4,835,252 shares, now holding 5,464,997 shares worth $455.18 million.
Kymera Therapeutics, Inc. Stock Down 2.9%
Shares of Kymera Therapeutics traded near $98.25 on Wednesday. The company boasts a market cap of approximately $8.18 billion and has a forward P/E ratio of -22.89, reflecting its unprofitability. The stock's 52-week range is between $36.65 and $105.00, with a 50-day moving average of $83.06 and a 200-day moving average of $73.55. The company maintains a strong liquidity position, with a current ratio of 10.81 and a quick ratio of 10.39, alongside a low debt-to-equity ratio of 5.23.
$KYMR stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Kymera Therapeutics reported revenue of $51.48 million with a growth rate of 55.5%. However, the company posted a net margin of 0.0% and a return on equity of -27.09%, indicating ongoing challenges in profitability. The next earnings announcement is scheduled for August 10, 2026.
Insider Buying and Selling at Kymera Therapeutics, Inc.
Several insider transactions were reported, including sales by Bruce Booth and Noah Goodman. On June 22, 2026, Goodman, the Chief Business Officer, sold 2,500 shares at an average price of $99.00 under a planned sale. On the same day, he also bought 2,500 shares at $21.05. Booth made several planned sales in June, including 278,128 shares at $99.12 and 115,056 shares at $91.01.
Analysts Set New Price Targets
On May 6, 2026, Canaccord Genuity initiated coverage on Kymera Therapeutics with a 'buy' rating and a price target of $106. Jefferies assumed coverage on March 16, 2026, also with a 'buy' rating and a target of $110. UBS, Citigroup, and Stephens & Co. maintained their 'buy' ratings with targets of $128, $120, and $100, respectively. The consensus among 21 analysts is a 'strong buy' with a mean target price of $119.19.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a biotechnology company based in Watertown, Massachusetts. Founded in 2015, it focuses on developing small molecule therapeutics that degrade disease-causing proteins. The company is advancing several candidates, including KT-621 for atopic dermatitis and KT-579 for autoimmune diseases. With a strategic alliance with Sanofi, Kymera is also exploring treatments for immunology-inflammation diseases.
Bottom Line
Driehaus Capital Management's decision to trim its stake in Kymera Therapeutics reflects a slight repositioning in its portfolio. Investors often track these filings for insights into institutional sentiment. However, it's important to remember that 13F filings are backward-looking and may not represent the current positions of the firm.
Get Kymera Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $KYMR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.